1800 244 735

Helpline (02) 9874 9777

Updates from the EHDN Plenary Meeting 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn and discuss some of the recent developments in Huntington’s disease research.

The Science Sessions

Lesley Jones (University of Cardiff, UK) chaired the first session which covered some of the latest research from labs around the world working on Huntington’s disease.

Frederic Saudou (INSERM, France) kicked things off with a talk about the function of the huntingtin protein. This is the protein encoded by the huntingtin gene which is mutated in patients with HD. This protein is one of the largest made in our bodies and it sticks to lots of other different proteins in the cell which makes it tricky for scientists to study. The Saudou lab is interested in the role of the huntingtin protein in moving capsules called vesicles in nerve cells, a process which is critical for brain function. Using “brain on a chip” technology, they can look at how vesicle movement changes in patients with HD as well how brain cells connect and work together in their HD models.

Next, Darren Monckton (University of Glasgow, UK) presented an update on his group’s research on somatic expansion. As HDBuzz recently wrote, somatic expansion is associated with the severity of HD and the increase of the CAG repeat length in the huntingtin gene in certain cells and tissue types can lead to earlier onset of symptoms. Recently, scientists have found that certain small changes in the code of DNA repair genes can affect the amount of somatic expansion that occurs. This makes sense of the genome-wide association study data which shows that these small variations in sequence of DNA repair genes can cause symptom onset to start earlier or later for patients. Understanding the precise mechanism and which genes are involved could open up lots of opportunities to develop new therapies for HD.

Hilal Lashuel (EPFL, Switzerland) next presented his lab’s recent findings which implicate a gene called TBK1 in HD. TBK1 is able to mark the huntingtin protein with a special label called phosphorylation. When the huntingtin protein is marked by TBK1, nerve cells survive much better in laboratory models of HD and this effect is reversed if the activity of TBK1 is blocked. If we could activate TBK1 in HD patients, this could be a new way to treat HD.

The final talk of the science session was from George McAllister (CHDI Foundation, USA) who spoke about promising new oral therapies for huntingtin lowering. Although not yet in the clinic, there are a number of companies, including Novartis and PTC, who are developing huntingtin lowering drugs which could be taken as a pill. This would mean avoiding the intrathecal (spinal tap) or intracranial (injection into the brain) methods of delivering the medicine which is what many of the huntingtin lowering therapies currently in clinical trials use. Researchers hope that this would make it easier for patients to take the medicine. Having an oral therapy would also mean that the whole body could be treated, not just the brain, which would have the bonus effect of making it easier to measure how well the drug is working by measuring in blood for example. The effects of the medicine would also be reversible if treatment was halted. However, there are lots of potential issues which scientists need to carefully consider such as whether targeting the whole body is appropriate or is there would be off target effects. Preclinical and clinical studies will hopefully provide answers and we look forward to reporting on these exciting new therapeutics in the coming year or so.

Clinical Study and Trial Updates

The next session of the day was chaired by Jean-Marc Burgunder (University of Bern, Switzerland) and focussed more of the clinical studies currently underway to find new treatments for HD.

This session started with a talk from Sarah Tabrizi (UCL, UK) which presented insights from the open label extension of Tominersen, the huntingtin lowering therapy developed by Roche. This extension study looks at the long-term safety of the treatment in a small group of premanifest HD patients over the course of 15 months. One of the key findings of the study was that waiting longer periods of time between doses of Tominersen still lowered huntingtin sufficiently, and that the more spaced out treatment regimen also resulted in fewer negative side effects for the treated patients. This 8-week treatment regimen will now be used in the GENERATION HD1 trial which will evaluate whether Tominersen treatment improves outcomes for HD patients. We know that this drug lowers huntingtin levels when we measure a treated patient’s spinal fluid, which clinicians use as a proxy for measuring huntingtin in the brain. Now the scientists need to work out if the huntingtin lowering is sufficient to improve patient symptoms. The trial is now fully enrolled and we are grateful to the 791 HD patients from around the world who signed up for this critical clinical trial. Despite the COVID-19 pandemic, Roche states that it is working hard to mitigate any effects to the ongoing trials whilst keeping patients, clinicians and HD families safe.

Next, Anna Heinzmann (ICM Institut du Cerveau, France) presented an update on the PRECISION-HD study, another huntingtin lowering therapy developed by Wave. Wave’s therapy specifically targets the mutated form of the huntingtin gene which could be a preferred approach as it leaves the unmutated huntingtin levels intact. However, this treatment is only available to patients that have a specific barcode in their DNA as this is how the drug targets the mutated version of HTT so not every patient is eligible. So far, the scientists at Wave have shown that their therapy is safe in patients but will follow up with more findings in the first quarter of 2021 which we hope will indicate how well their drug is working to lower the mutated from of HTT.

The following presentation gave an overview of the SHIELD HD natural history study, which is being run by Triplet Therapeutics. Anne Rosser (University of Cardiff, UK) explained how this study will lay the groundwork for future clinical trials which aim to target DNA damage repair pathways. Triplet have shown in the HD mouse models that reducing the levels of certain DNA damage repair proteins can halt the process of somatic expansion. By targeting somatic expansion in this way, Triplet hopes to treat the underlying pathology of HD. They are running this natural history study in order to inform the design of a future clinical trial and to work out what measures they might need to take of patients to find out if their therapy is working. The HD patients enrolled in this study will be assessed by a variety of methods over the course of 2 years by clinicians and both the data and samples (such as blood) taken from the patients, will be critical for scientists to better design the future clinical trials.

Bernhard Landwehrmeyer (Ulm University, Germany) gave the next talk about PROOF-HD which will assess the potential for treating HD patients with the drug Pridopidine. Scientists have recently made headway in understand how Pridopidine might be working and think its acts through a type of nerve cell receptor called the sigma 1 receptor. Activating this receptor, as Pridopidine is believed to do, is thought to have a variety of downstream effects which are hoped to improve HD patient outcomes. Although earlier trials for Pridopidine had disappointing results, this new trial hopes that by looking at treating early manifest patients for much longer they may see better outcomes for patients.

Ralf Reilmann (George Huntington Instititut, Germany) presented an update on the Uniqure AAV gene therapy which also aims to lower huntingtin. Uniqure’s AMT-130 therapy is delivered in a one-shot brain surgery and this virus-based approach irreversibly alters the patient’s DNA resulting in reduced HTT levels. Scientists have been able to show that this treatment is both safe and effective at lowering HTT in both small and large animal models of HD such as rats, pigs and monkeys. The current AMT-130-01 study will look at how this translates into humans and whether the drug is still safe in the small number of patients who will receive it. 26 patients will receive the therapy by brain surgery and will be monitored at specialist HD clinics around the world. Enrollment is ongoing in the US for the study.

Anne-Catherine Bachoud-Levi (INSERM, France) gave a talk about the MIG-HD clinical trial. This trial investigated the use of stem cells in treating HD in a long clinical study spanning more than a decade. Although the treatment tested in this specific trial was not successful in treating HD, the scientists learnt a lot about best practises for this type of stem cell transplantation treatment. Since the trial, there have been huge breakthroughs in our understanding of stem cells. Bachoud-Levi and team are hopeful that new stem cell-based therapies may help HD patients in the future.

The final talk of the day was from Hugh Rickards (University of Birmingham, UK) who discussed the Huntington’s equal access to effective drugs (HEATED) project. As there are an increasing number of very exciting drugs in clinical trials, many people in the HD research community expect there to be a few which might be approved for use in HD patients. However, it is likely that these might be very expensive meaning that not all HD patients would be able to access them immediately. Rickards is working to understand the challenges of HD drug affordability and accessibility to ensure as many patients as possible are able to access therapies when they become available.

Rewatch online

You can watch all of the talks on the EHDN website. To find out more about the current HD clinical trials, visit HD Trial Finder.

Latest Research Articles

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Published date: 9 December, 2022

The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment in Huntington’s disease (HD). This news comes following recent bad news about side effects of branaplam in HD patients, being tested in the VIBRANT-HD clinical trial, dosing of which was ... Read more

Update on the PTC Therapeutics PIVOT-HD Trial

Published date: 2 November, 2022

Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of different (and confusing!) headlines about the pause in recruitment. In this article, we will lay out what is going on and what this announcement means. What is the aim of ... Read more

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Published date: 30 September, 2022

In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. First, the pharmaceutical company Roche announced plans for a new clinical trial of tominersen. Then, the genetic medicines company Wave Life Sciences shared early data showing that its ... Read more

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more